Edema Patents (Class 514/870)

Cross-Reference Art Collections

Topical (Class 514/871)
  • Patent number: 10709682
    Abstract: The present invention relates to the treatment or prevention of tinnitus. More precisely, the present invention relates to a compound modulating chloride co-transporter NKCC1 (chloride co-transporter modulator) for use in the treatment of tinnitus. In addition, the present invention concerns pharmaceutical compositions comprising such an NKCC1 chloride co-transporter modulator as an active agent, a method for the treatment or prevention of tinnitus by administering such a chloride co-transporter modulator, and a screening method for the identification and characterization of compounds capable of modulating chloride co-transporter NKCC1.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 14, 2020
    Assignee: Otolanum AG
    Inventors: Marlies Knipper-Breer, Luckas Ruettiger
  • Patent number: 10071953
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: September 11, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns, Jeffrey Winkler, Barry Twenter
  • Patent number: 8980952
    Abstract: The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: March 17, 2015
    Assignees: University of Maryland, Baltimore, The United States of America as represented by the Dept. of Veterans Affairs
    Inventors: J. Marc Simard, Mingkui Chen
  • Patent number: 8889115
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: November 18, 2014
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, Han-Ting Chang, Gerrit Klaerner, Jerry M. Buysse, Mingjun Liu
  • Patent number: 8609734
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: December 17, 2013
    Assignee: Pathdogica, LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Patent number: 8569377
    Abstract: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: October 29, 2013
    Assignees: The United States of America as Represented by the Department of Veteran Affairs, University of Maryland, Baltimore
    Inventor: J. Marc Simard
  • Patent number: 8409561
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: April 2, 2013
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Futian Liu, Gerrit Klaerner
  • Patent number: 8409624
    Abstract: The present invention provides an artificial cerebrospinal fluid containing 120 to 160 mEq/L of sodium ion, 1 to 6 mEq/L of potassium ion, 75 to 155 mEq/L of chloride ion, and 5 to 45 mEq/L of bicarbonate ion, and provides an artificial cerebrospinal fluid further containing at least one component selected from the group consisting of 10 g/L or less of a reducing sugar, 5 mmol/L or less of phosphoric acid, 5 mEq/L or less of calcium ion, and 5 mEq/L or less of magnesium ion. The artificial cerebrospinal fluid of the present invention can prevent or reduce the incidence of cerebral edema and can further suppress brain cell disorders when used as an irrigation fluid or perfusion fluid in the field of neurosurgery, such as intracranial surgery, or when used as a replenishing fluid for lost cerebrospinal fluid.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: April 2, 2013
    Assignee: Otsuka Pharmaceutical Factory, Inc.
    Inventors: Kazuhisa Doi, Yujiro Morioka, Takeshi Kawano
  • Patent number: 8372799
    Abstract: A protein which is composed N-terminally of one or several C-terminal parts of the amino acid sequence of the mature tumor necrosis factor and C-terminally of one or several N-terminal parts of the amino acid sequence of the mature tumor necrosis factor, which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: February 12, 2013
    Assignee: Apeptico Forschung und Entwicklung GmbH
    Inventors: Bernhard Fischer, Rudolf Lucas
  • Patent number: 8318810
    Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: November 27, 2012
    Assignees: University of Maryland, Baltimore, The United States of America as represented by the Department of Veterans Affairs
    Inventors: J. Marc Simard, Mingkui Chen
  • Patent number: 7872048
    Abstract: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: January 18, 2011
    Assignee: University of Maryland, Baltimore
    Inventor: J. Marc Simard
  • Patent number: 7816374
    Abstract: A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: October 19, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gerald J. Gleich, Loren W. Hunt, Jr.
  • Patent number: 7776319
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: August 17, 2010
    Assignee: Relypsa, Inc.
    Inventors: Robert Alpern, Jerry Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner, Eric Connor, Mingjun Liu, Futian Liu, Jun Shao
  • Patent number: 7468362
    Abstract: Compositions containing ?2 adrenergic agonists in combination with carbonates and carbonates of the formula and in combination with related steroid carbonates and carbonates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilator and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: December 23, 2008
    Assignee: Sepracor Inc.
    Inventors: Mark G. Currie, Steve Jones, Paul Grover, Chris H. Senanayake, Q. Kevin Fang
  • Patent number: 7285574
    Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: October 23, 2007
    Assignee: University of Maryland, Baltimore
    Inventors: J. Marc Simard, Mingkui Chen
  • Patent number: 7147864
    Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: December 12, 2006
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Mark G. Resnick
  • Patent number: 7097860
    Abstract: A method of reducing inflammation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: August 29, 2006
    Inventors: Aaron Moshenyat, Anna Moshenyat, Reuven Moshenyat, Yitzchak Moshenyat
  • Patent number: 6841551
    Abstract: A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: January 11, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alan John Nimmo, Robert Vink
  • Patent number: 6828349
    Abstract: The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a mammal suffering from substance addiction. The method includes administering to a mammal an effective amount of gamma vinylGABA or a pharmaceutically acceptable salt thereof. The present invention also provides a method of treatment of cocaine, morphine, heroin, nicotine, amphetamine, methamphetamine, or ethanol addiction by treating a mammal with an effective amount of gamma vinylGABA or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 1998
    Date of Patent: December 7, 2004
    Assignee: Brookhaven Science Associates
    Inventors: Stephen L. Dewey, Jonathan D. Brodie, Charles R. Ashby, Jr.
  • Patent number: 6709664
    Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: March 23, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Mark G. Resnick
  • Patent number: 6500809
    Abstract: Neural tissue edema is treated by circulating a hyperoncotic artificial cerebrospinal fluid in the cerebrospinal fluid pathway in the vicinity of edematous tissue to cause the edematous tissue to be dehydrated due to an oncotic gradient between the hypertonic artificial cerebrospinal fluid and intracellular fluid and withdrawing the fluid from the pathway after it has been so circulated.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: December 31, 2002
    Assignee: Neuron Therapeutics, Inc.
    Inventor: Glenn Frazer
  • Patent number: 6462016
    Abstract: There are provided a method to screen agonist or antagonist of the maxadilan receptor participating in vasodilating action, wherein a receptor of maxadilan is used, compounds which specifically bind to the receptor, and a tissue preparation having the receptor. The compounds are variants of maxadilan from the salivary glands of the sand fly.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: October 8, 2002
    Assignees: Shiseido Company, Ltd., The General Hospital Corporation
    Inventors: Kawori Wakita, Osamu Moro, Manami Ohnuma, Ethan A. Lerner, Masahiro Tajima
  • Patent number: 6258846
    Abstract: The present disclosure relates to novel nutritional compositions containing linoleic acid and/or linolenic acid which optimize child neurological development and provide improved nutritional support for women prior to and during lactation. The nutritional compositions are intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: July 10, 2001
    Assignee: Drugtech Corporation
    Inventors: Marc S. Hermelin, R. Saul Levinson, George Paradissis
  • Patent number: 6238707
    Abstract: The present invention comprises a selection of herbal, organic and inorganic materials with curative effects combined in a powdered form for human ingestion. The demonstrated benefits on human female hormone regulation or replacement include return from irregular to regular and less painful menstrual cycles, raising estrogen and progesterone levels to normal levels through menstrual cycles, return to regular menstrual cycle hormone levels with apparent infertility cure, and return to normative metabolic response from apparent circulatory abnormalities such as excessive sweating, edema, cold hand and feet, stiffness and other such symptoms.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: May 29, 2001
    Inventor: Zhang Chun
  • Patent number: 6136862
    Abstract: A cerebral function improving agent containing as the active ingredient a compound represented by the following formula: ##STR1## wherein R.sub.2 represents a hydrogen atom when R.sub.1 is a hydroxyl group;or R.sub.1 or R.sub.1 are combined together to form an oxo group;R.sub.3 represents a hydrogen atom, an alkali metal, or a monohydric, dihydric or trihydric alcohol residue,which may be an oligomer composed of 2-10 molecules when R.sub.1 represents a hydroxyl group and R.sub.2 and R.sub.3 represent hydrogen atoms.The agent suppresses cerebral edema, protects cerebral function, impaired cerebral energy metabolism, and reduces the extent of cerebral infarction.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: October 24, 2000
    Assignee: Shimizu Pharmaceutical Co., Ltd.
    Inventors: Atsushi Hiraide, Sekiko Dohi, Motohisa Suzuki, Yoshihiro Shiba
  • Patent number: 5945448
    Abstract: The present invention relates to a composition for treating or preventing brain edemas which comprises containing an endothelin antagonist as an active ingredient, for example, the compound of the following formula (I): ##STR1## or pharmaceutically acceptable salts or hydrates thereof, bosentan, cyclo?D-aspartyl-L-?3-(4-phenylpiperazin-1-ylcarbonyl)!-alanyl-L-aspartyl- D-?2-(2-thienyl)!glycyl-L-leucyl-D-tryptophyl!disodium or cyclo ?D-Asp-L-Pro-D-Val-L-Leu-D-Trp!.Furthermore, the present invention provides a method for treating or preventing brain edemas, which comprises administering an effective amount of an endothelin antagonist and use of an endothelin antagonist for the manufacture of a medicament for treating or preventing brain edemas.An endothelin antagonist exhibits an inhibitory effect, on all brain edemas regardless of the onset mechanism and thus is highly useful in the treatment or prevention of brain edemas.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: August 31, 1999
    Assignee: Shionogi & Co., Ltd.
    Inventors: Mitsuyoshi Ninomiya, Yoshiyuki Matsuo
  • Patent number: 5912018
    Abstract: The present invention provides an epidermal gel secretion of Arabian Gulf catfish which is useful in enhancing wound healing, alleviating muscle spasms and pain, and treating dermatological disorders.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: June 15, 1999
    Inventor: Jassim M. Al-Hassan
  • Patent number: 5886053
    Abstract: The use of carotenoids for producing drugs for the treatment of inflammatory disorders not caused by the action of light or an infection with microorganisms.
    Type: Grant
    Filed: July 30, 1997
    Date of Patent: March 23, 1999
    Assignee: BASF Aktiengesellschaft
    Inventors: Wolfgang Schmutzler, Karl Kolter
  • Patent number: 5776504
    Abstract: A magnesium-taurine compound and its method of synthesis. The compound is synthesized by reacting taurine and magnesium in a 2:1 molar ratio. The resulting mixture is diluted with methanol and the remaining clear filtrate is crystallized from methanol. This compound may be administered orally as a nutritional supplement or may be administered orally or intravenously for the therapeutic or prophylactic treatment of pre-eclampsia/eclampsia and acute cardiac conditions.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: July 7, 1998
    Assignee: Nutrition 21
    Inventor: Mark F. McCarty
  • Patent number: 5646156
    Abstract: The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: July 8, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Marlene A. Jacobson, Robert G. Johnson, Christopher A. Salvatore
  • Patent number: 5530001
    Abstract: A novel pharmaceutical use of a dihydropyridine derivative of the formula (I) ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and each is an alkyl or the like; R.sub.4 is a hydrogen atom or the like; R.sub.5 is nitro, a halogenated alkyl, cyano or the like; X is a vinylene or an azomethine; A is an alkylene; and B is --N(R.sub.6) (R.sub.7) or a group of the formula ##STR2## wherein R.sub.6 and R.sub.7 are the same or different and each is an alkyl, an aralkyl, an aryl or the like; R.sub.8 and Ar are aryl or the like; and n is 0, 1 or 2, or an acid addition salt thereof for promoting PGI.sub.2 production, and for the treatment and prevention of hyperlipemia, arteriosclerosis and cerebral diseases.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: June 25, 1996
    Assignee: The Green Cross Corporation
    Inventors: Masahide Nakajima, Norifumi Nakamura, Feng Wang, Koichi Yamanouchi, Kazutaka Hayashi, Hideaki Kido, Yoshiji Kubo, Minori Okita, Takeshi Uchida, Masahiro Watanabe, Katsumi Yamanaga, Hiroshi Shinyama, Toru Kawamura, Yuji Narita
  • Patent number: 5478844
    Abstract: A novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least: one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: December 26, 1995
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tetsuya Aono, Shigenori Ohkawa, Takayuki Doi
  • Patent number: 5466667
    Abstract: Unique methods for treating edemas in living subjects are provided comprising administering an effective amount of an antamanide or an antamanide analogue to the subject. The methods offer prophylactic and therapeutic modes of treatment for both localized and systemic edemas. The antamanides and antamanide analogues may be applied topically or given parenterally; and may be employed with other diverse agents for treatment of both inflammatory and non-inflammatory edemas.
    Type: Grant
    Filed: September 22, 1993
    Date of Patent: November 14, 1995
    Assignee: Trustees of Boston University
    Inventors: David Shepro, J. Steven Alexander
  • Patent number: 5409903
    Abstract: A method of treating a mammal for the presence or the activity of H. pylori in the gastrointestinal tract is disclosed. The method encompasses orally administering to said mammal a sufficient amount of a scavenging, reacting or inactivating compound to remove bicarbonate ions, ammonium ions or urea which are present in combination with the microorganisms which colonize and infect the gastric mucosa. Such microorganisms have been implicated in gastritis, gastric ulcer disease and as a risk factor in gastric carcinoma.Also, the invention encompasses a method, utilizing similar compounds, for the treatment or prevention of dermatitis such as diaper rash wherein these compounds are preapplied to the skin or used to treat the diaper prior to use.Also included are compositions which are used for the methods described above.
    Type: Grant
    Filed: February 18, 1992
    Date of Patent: April 25, 1995
    Assignee: Urecap Corporation
    Inventors: Robert B. Polak, Attallah Kappas
  • Patent number: 5278143
    Abstract: Unique methods for treating interleukin-mediated edemas in living subjects are provided comprising administering an effective amount of a composition selected from the group consisting of phallotoxins, phallotoxin analogues, antamanide, or an antamanide analogue to the subject. The methods offer prophylactic and therapeutic modes of treatment for both localized and systemic interleukin-mediated edemas. The compositions of choice may be applied topically or given parenterally; and may be employed with other diverse agents for treatment of both inflammatory and non-inflammatory edemas.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: January 11, 1994
    Assignee: Trustees of Boston University
    Inventors: David Shepro, J. Steven Alexander
  • Patent number: 5188838
    Abstract: Process for the preparation of pearls based on a pharmaceutical active substance exhibiting an indefinite crystallization point. The said active substance is mixed in molten form which a pharmaceutical excipient promoting the solidification of the active substance, the melt is forced to pass through a nozzle which is subjected to a vibration, the pearls formed are allowed to fall in a tower countercurrentwise to a gas, and the pearls formed are collected in the bottom of the tower.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: February 23, 1993
    Assignee: Rhone-Poulenc Sante
    Inventors: Michel Deleuil, Pierre Labourt-Ibarre, Robert Rona, Eraclis Statiotis
  • Patent number: 5182299
    Abstract: A method of treating an osmotic disturbance in an animal which comprises administering to an animal an effective amount of an organic osmolyte, wherein the organic osmolyte is a polyol. Specific polyols include myo-inositol and sorbitol. Also included are precursors of organic osmolytes including precursors of polyols. Other polyol precursors are selected from the group consisting of glucose, glucose polymers, and glycerol. Also incluThis invention was funded by a research grant from the National Institutes of Health, 1RO1 DK36031, which provides to the United States Government certain rights in the invention.
    Type: Grant
    Filed: March 19, 1991
    Date of Patent: January 26, 1993
    Assignee: Brigham and Women's Hospital
    Inventors: Steven R. Gullans, Charles W. Heilig
  • Patent number: 5047429
    Abstract: A method is described for treating and/or preventing pulmonary oedema in patients comprising administering a suphonylurea compound or a pharmaceutically acceptable salt thereof to patients who suffer from or are susceptible to oedema. Glucose may also be simultaneously administered to the patients to prevent hypoglycemia.
    Type: Grant
    Filed: April 18, 1989
    Date of Patent: September 10, 1991
    Assignee: Hoechst Aktiengesellschaft
    Inventor: Piers C. G. Nye
  • Patent number: 5032612
    Abstract: A mouthwash is disclosed and claimed which comprises silver acetate, ammonium nitrate, and nitric acid which, when present as a residue in the oral cavity, will cause an adverse taste when the user smokes a tobacco product. The bitter taste experience causes the development of an aversion to smoking. The use of other non-toxic silver compounds is also disclosed.
    Type: Grant
    Filed: May 25, 1990
    Date of Patent: July 16, 1991
    Inventors: Milan J. Smolko, Milan S. Smolko
  • Patent number: 4992469
    Abstract: A quinone derivative of the formula (I): ##STR1## in which A is a group of the formula (IV): ##STR2## or a group of the formula (V): ##STR3## in which X and Y are either the same as or different from each other and each are hydroxy, methoxy or hydrogen; and n is an integer of 1 to 5,is disclosed. The compound is useful as a medicament.
    Type: Grant
    Filed: May 29, 1985
    Date of Patent: February 12, 1991
    Assignees: Eisai Co., Ltd., Nagoya University
    Inventors: Takayuki Ozawa, Morimitsu Nishikimi, Hiroshi Suzuki, Yoshiharu Shimomura, Isao Yamatsu, Shinya Abe, Kouji Yamada, Tohru Fujimori, Takanobu Takamura
  • Patent number: 4970301
    Abstract: Compound of general formula I: ##STR1## in which: A is a single or double bond,R.sub.1 and R.sub.3, which may be identical or different, are each a hydrogen atom, an alkoxycarbonylmethylene radical of formula --CH.sub.2 CO.sub.2 R.sub.4 (in which R.sub.4 denotes an alkyl radical having 1 to 5 carbon atoms) or a radical of formula W: ##STR2## (in which n is equal to 0 or 1 and R.sub.5, R.sub.6 and R.sub.7, which may be identical or different, are each a hydrogen or halogen atom, a hydroxyl radical, a trifluoromethyl radical, a lower alkyl radical containing 1 to 5 carbon atoms or an alkoxy radical containing 1 to 5 carbon atoms),R.sub.2 is a hydrogen atom, an alkoxycarbonylmethylene radical of formula --CH.sub.2 CO.sub.2 R.sub.4, a radical of formula W, or a .beta.-glucose or rutinose molecule linked to the oxygen to which it is attached with a glycoside bond,on condition, however, that at least either R.sub.1 or R.sub.2 or R.sub.
    Type: Grant
    Filed: November 29, 1988
    Date of Patent: November 13, 1990
    Assignee: Adir et Cie
    Inventors: Yves Rolland, Jacques DuHault
  • Patent number: 4959355
    Abstract: This invention provides a method of inhibiting osmotic water flow across mammalian cell membranes which involves contacting the water channels of the cell membranes with an effective amount of a glucose transport blocker or of digitonin so as to inhibit osmotic water flow across the membranes.Additionally, this invention provides a method of treating a subject afflicted with a condition associated with abnormal osmotic water flow across cell membranes which comprises administering to the subject an effective amount of a glucose transport blocker or of digitonin so as to contact the water channels of the subject's cell membranes and inhibit osmotic water flow across the membranes.
    Type: Grant
    Filed: March 16, 1987
    Date of Patent: September 25, 1990
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jorge Fischbarg, Larry S. Liebovitch, Jan P. Koniarek
  • Patent number: 4946832
    Abstract: Cosmetic Base composition exhibiting therapeutic properties comprising an acyl fatty acid alpha-hydroxy carboxylic acid ester or alkali metal salt thereof, a sucrose fatty acid ester, and a solvent.
    Type: Grant
    Filed: July 21, 1988
    Date of Patent: August 7, 1990
    Assignee: R.I.T.A. Corporation
    Inventors: Stephen T. Goode, Robert R. Linton, Fred Baiocchi
  • Patent number: 4851450
    Abstract: The present invention is a group of biologically active agents, di-hydroxy alkyl glycerols with vicinal hydroxyl groups and their acetyl-derivatives having the general formula: ##STR1## where R is selected from the group of H and CH.sub.3 CO-- and x+y is between 9 and 21; and methods for their synthesis. The compounds of the present invention are synthesized starting with an unsaturated 1-O-alkyl-glycerol of the formula: ##STR2## where R is an unsaturated alkyl group with a chain length of 12 to 24 carbon atoms and introducing a vicinal hydroxyl into the alkyl carbon chain using either osmium tetroxide or performic acid, produced by mixing formic acid with hydrogen peroxide.The new glycerol ether derivatives exert platelet activating factor (PAF)-like action in vitro in low concentrations, and, surprisingly, in higher doses act as selective antagonists of PAF, or 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC), activities.
    Type: Grant
    Filed: October 26, 1987
    Date of Patent: July 25, 1989
    Inventor: Constantine A. Demopoulos
  • Patent number: 4822601
    Abstract: Cosmetic Base composition exhibiting therapeutic properties includes an acyl fatty acid lactylate ester or alkali metal salt thereof, a sucrose fatty acid ester, and a solvent.
    Type: Grant
    Filed: March 13, 1987
    Date of Patent: April 18, 1989
    Assignee: R.I.T.A. Corporation
    Inventors: Stephen T. Goode, Robert R. Linton, Fred Baiocchi
  • Patent number: 4542026
    Abstract: An agent and method for treating vasomotor disorders, particularly migraine and menstrual pain is provided wherein the method comprises administering to said patient, intravenously or orally, an effective dose of the agent according to the invention, Vitamin B.sub.6. The effective dose of vitamin B.sub.6 is at least about 100 mg., preferably at least about 300 mg. and most preferably at least about 400 mg. Vitamin B.sub.2 may also be administered for particularly effective results.
    Type: Grant
    Filed: April 29, 1983
    Date of Patent: September 17, 1985
    Inventor: Jose Rios
  • Patent number: 4510322
    Abstract: The uricosuric and diuretic properties of indacrinone, [6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-2-phenyl-1H-inden-5-yl)oxy]acetic acid, are carefully balanced for maximum therapeutic benefit by manipulation of the proportion of (+) and (-) enantiomers in the final product within critical limits.
    Type: Grant
    Filed: February 3, 1983
    Date of Patent: April 9, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Edward H. Blaine, Edward J. Cragoe, Jr., Ralph F. Hirschmann, John F. Nancarrow, deceased, by Elisabeth M. Nancarrow, executrix, Jonathan A. Tobert